Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13035866 | 0.94 | GRIN2D (0.36) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL25738613 | 0.88 | GRIN2D (0.32) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL18399869 | 0.86 | SOS1 (0.32) | — | |
| SCHEMBL25696632 | 0.86 | — | — | |
| SCHEMBL15383166 | 0.84 | SOS1 (0.31) | — | |
| SCHEMBL25696625 | 0.81 | — | — | |
| SCHEMBL19766549 | 0.79 | SOS1 (0.31) | — | |
| SCHEMBL26080396 | 0.79 | SOS1 (0.31) | — | |
| SCHEMBL16816271 | 0.79 | SOS1 (0.31) | — | |
| SCHEMBL26419322 | 0.78 | GRIN2D (0.37) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691975-B2 | MAGL inhibitors | H. LUNDBECKA/S (DK) | 2023-07-04 | — | — | US | disclosed |
| US-11691975-B2 | MAGL inhibitors | H. LUNDBECKA/S (DK) | 2023-07-04 | — | — | US | disclosed |
| US-20220135563-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-05-05 | — | — | US | disclosed |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| US-11059822-B2 | MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-07-13 | — | — | US | disclosed |
| US-20200291023-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-09-17 | — | — | US | disclosed |
| US-20100280057-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | BURNS BARBIER LINDSAY | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059822-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | GRIN2D 1240/4885GRIN3B 275/4885CHRM2 3849/4885 |
| US-20220135563-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | GRIN2D 1240/4885GRIN3B 275/4885CHRM2 3849/4885 |
| US-20200291023-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | GRIN2D 1240/4885GRIN3B 275/4885CHRM2 3849/4885 |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | MGLL, LIPA, PNLIP | GRIN2D 4183/4885GRIN3B 2784/4885CHRM2 4372/4885 |
| US-20100280057-A1 | NOVEL ANALGESIC THAT BINDS FILAMIN A | FLNA, OPRL1, FLNB | GRIN2D 1140/4885GRIN3B 355/4885CHRM2 610/4885 |
| US-11691975-B2 | MAGL inhibitors | MAG, MAGI3, MGLL | GRIN2D 1240/4885GRIN3B 275/4885CHRM2 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.